Exhibit 99.1 Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 -- -- Enrolling 2L LBCL and prior CD19 relapsed LBCL patients based on CB-010 ANTLER Phase 1 data presented at 2024 ASCO Annual Meeting; data to be presented H1 2025 -- -- $311.8 million in cash, cash equivalents, and marketable securities expected to fund ...

Company Overview - Caribou Biosciences, Inc. (CRBU) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2024 [1] - The consensus estimate indicates a quarterly loss of $0.45 per share, reflecting a year-over-year change of +6.3% [3] - Revenues are projected to be $3.31 million, down 12% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 1.08% higher over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Caribou Biosciences is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.67% [10] - The stock currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [10] Earnings Surprise History - In the last reported quarter, Caribou Biosciences was expected to post a loss of $0.39 per share but actually reported a loss of $0.46, resulting in a surprise of -17.95% [11] - Over the last four quarters, the company has beaten consensus EPS estimates two times [12] Industry Context - Fortrea Holdings Inc. (FTRE), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post earnings of $0.07 per share for the quarter ended June 2024, indicating a year-over-year change of -86.5% [16] - Fortrea's revenue is expected to be $686.08 million, down 13.5% from the previous year [16] - The consensus EPS estimate for Fortrea has been revised 2.7% higher over the last 30 days, but it has an Earnings ESP of -17.91% [17]

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Caribou and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On June ...

BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of ...

-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases - - BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune dis ...

The investigation concerns whether Caribou and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On June 2, 2024, Caribou issued a press release announcing that the Company had "presented updated clinical data from the ongoing ANTLER Phase 1 trial that indicates a single dose of CB-010, a readily available, offthe-shelf anti-CD19 CAR-T cell therapy with a PD-1 knockout, has the potential to rival the safety, efficacy, and durability of approved a ...

-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved o ...

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -17.95%. A quarter ago, it was expected that this company would post a loss of $0.22 per share when it actually produced a loss of $0.39, delivering a surprise of -77.27%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Registrant's telephone number, including area code: (510) 982-6030 ______________________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par ...

Exhibit 99.1 Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- $345.9 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q1 2026 -- "We continue to focus on advancing four clinical-stage programs, including the parallel development of ...